Moderna Inc (MRNA) - Total Assets
Based on the latest financial reports, Moderna Inc (MRNA) holds total assets worth $10.96 Billion USD as of June 2026. Total assets represent everything the company owns and controls, combining both current assets—like cash and cash equivalents, accounts receivable, and inventories—and non-current assets such as property, plant, equipment (PP&E), intangible assets, and long-term investments.
Moderna Inc - Total Assets Trend (2014–2025)
This chart illustrates how Moderna Inc's total assets have evolved over time, based on quarterly financial data. Also see MRNA market cap overview for the company's overall valuation and market capitalisation.
Moderna Inc - Asset Composition Analysis
Current Asset Composition (December 2025)
Moderna Inc's total assets of $10.96 Billion consist of 53.0% current assets and 47.0% non-current assets. Review Moderna Inc (MRNA) total liabilities to assess the company's total debt and financial obligations.
| Asset Category | Amount (USD) | % of Total Assets |
|---|---|---|
| Cash & Equivalents | $0.00 | 21.0% |
| Accounts Receivable | $284.00 Million | 2.3% |
| Inventory | $153.00 Million | 1.2% |
| Property, Plant & Equipment | $0.00 | 0.0% |
| Intangible Assets | $45.00 Million | 0.4% |
| Goodwill | $52.00 Million | 0.4% |
Asset Composition Trend (2014–2025)
This chart illustrates how Moderna Inc's asset composition has evolved over time. Understanding changes in asset allocation can provide insights into the company's strategic shifts, capital allocation priorities, and business focus evolution. See Moderna Inc stock price for real-time trading data and today's change.
Key Asset Composition Facts
- Current vs. Non-Current Assets: Moderna Inc's current assets represent 53.0% of total assets in 2025, an increase from 27.3% in 2014.
- Cash Position: Cash and equivalents constituted 21.0% of total assets in 2025, up from 19.8% in 2014.
- Tangible vs. Intangible: Intangible assets (including goodwill) make up 0.0% of total assets, a decrease from 72.0% in 2014.
- Asset Diversification: The largest asset category is accounts receivable at 2.3% of total assets.
Moderna Inc Competitors by Total Assets
Key competitors of Moderna Inc based on total assets are shown below.
| Company | Country | Total Assets |
|---|---|---|
|
Royalty Pharma Plc
NASDAQ:RPRX
|
USA | $19.82 Billion |
|
Viking Therapeutics Inc
NASDAQ:VKTX
|
USA | $715.73 Million |
|
Xiamen Amoytop Biotech Co Ltd
SHG:688278
|
China | CN¥3.21 Billion |
|
Soleno Therapeutics Inc
NASDAQ:SLNO
|
USA | $608.39 Million |
|
SOLENO THERAPEUT. DL-001
F:6XC
|
Germany | €563.83 Million |
|
Taysha Gene Therapies Inc
NASDAQ:TSHA
|
USA | $470.43 Million |
|
Sinopep-Allsino Biopharmaceutical Co. Ltd. A
SHG:688076
|
China | CN¥7.07 Billion |
|
CureVac NV
F:5CV
|
Germany | €1.14 Billion |
Moderna Inc - Liquidity and Working Capital Analysis
Liquidity ratios measure a company's ability to pay off its short-term debts as they come due, using the company's current or quick assets. Working capital represents the operational liquidity available.
Key Liquidity Metrics
| Metric | Current | 1 Year Ago | 5 Years Ago |
|---|---|---|---|
| Current Ratio | 2.29 | 3.93 | 1.35 |
| Quick Ratio | 2.18 | 3.77 | 1.25 |
| Cash Ratio | 0.00 | 0.00 | 0.00 |
| Working Capital | $3.28 Billion | $4.60 Billion | $3.47 Billion |
Moderna Inc - Advanced Valuation Insights
This section examines the relationship between Moderna Inc's asset base and its market valuation, helping to identify whether the company's assets are efficiently translated into market value.
Key Valuation Metrics
| Current Price-to-Book Ratio | 8.29 |
| Latest Market Cap to Assets Ratio | 4.39 |
| Asset Growth Rate (YoY) | -12.8% |
| Total Assets | $12.34 Billion |
| Market Capitalization | $54.14 Billion USD |
Valuation Analysis
Premium Asset Valuation: The market values Moderna Inc's assets at a significant premium (4.39x), suggesting investors see substantial growth potential or unique competitive advantages.
Significant Asset Reduction: Moderna Inc's assets decreased by 12.8% over the past year, potentially indicating divestiture, restructuring, or challenging business conditions.
Annual Total Assets for Moderna Inc (2014–2025)
The table below shows the annual total assets of Moderna Inc from 2014 to 2025.
| Year | Total Assets | Change |
|---|---|---|
| 2025-12-31 | $12.34 Billion | -12.76% |
| 2024-12-31 | $14.14 Billion | -23.25% |
| 2023-12-31 | $18.43 Billion | -28.74% |
| 2022-12-31 | $25.86 Billion | +4.82% |
| 2021-12-31 | $24.67 Billion | +236.23% |
| 2020-12-31 | $7.34 Billion | +361.61% |
| 2019-12-31 | $1.59 Billion | -19.00% |
| 2018-12-31 | $1.96 Billion | +80.93% |
| 2017-12-31 | $1.08 Billion | -23.47% |
| 2016-12-31 | $1.42 Billion | +541115.13% |
| 2015-12-31 | $261.85K | -97.16% |
| 2014-12-31 | $9.22 Million | -- |
About Moderna Inc
Moderna, Inc., a biotechnology company, provides messenger RNA medicines in the United States, Europe, and internationally. The company's respiratory vaccines include spikevax, mNEXSPIKE, mRESVIA, COVID, RSV, seasonal influenza, combination, and pandemic influenza vaccine; latent vaccines comprise cytomegalovirus, epstein-barr virus, and human immunodeficiency virus vaccines; enteric viruses incl… Read more